对三种新型喹诺酮类药物（司帕沙星、CI-960和PD 131,628）的体外活性与环丙沙星对5252株临床分离细菌的活性进行多中心评估。
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
作者信息
Fuchs P C, Barry A L, Pfaller M A, Allen S D, Gerlach E H
机构信息
St. Vincent Hospital and Medical Center, Portland, Oregon 97225.
出版信息
Antimicrob Agents Chemother. 1991 Apr;35(4):764-6. doi: 10.1128/AAC.35.4.764.
Abstract
The in vitro activities of three new quinolones (sparfloxacin, CI-960, and PD 131,628) were compared with that of ciprofloxacin against 5,252 routine clinical aerobic and facultatively anaerobic bacterial isolates. Overall, CI-960 was the most active drug in vitro (MIC for 90% of the strains tested, 0.13 micrograms/ml); ciprofloxacin and sparfloxacin were the least active (MIC for 90% of the strains tested, 1.0 micrograms/ml). All three new quinolones, but particularly CI-960 and PD 131,628, exhibited significantly greater activity than ciprofloxacin against enterococci and staphylococci.
摘要
将三种新型喹诺酮类药物（司帕沙星、CI-960和PD 131,628）的体外活性与环丙沙星针对5252株常规临床需氧菌和兼性厌氧菌分离株的活性进行了比较。总体而言，CI-960是体外活性最强的药物（90%受试菌株的MIC为0.13微克/毫升）；环丙沙星和司帕沙星活性最低（90%受试菌株的MIC为1.0微克/毫升）。所有三种新型喹诺酮类药物，尤其是CI-960和PD 131,628，对肠球菌和葡萄球菌的活性明显高于环丙沙星。
相似文献
1
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates.
Antimicrob Agents Chemother. 1991 Apr;35(4):764-6. doi: 10.1128/AAC.35.4.764.
2
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
3
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Antimicrob Agents Chemother. 1992 May;36(5):1158-62. doi: 10.1128/AAC.36.5.1158.
4
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.
5
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
J Antimicrob Chemother. 1993 Apr;31(4):505-22. doi: 10.1093/jac/31.4.505.
6
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Chemotherapy. 1993;39(1):32-5. doi: 10.1159/000238970.
7
The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
J Antimicrob Chemother. 1991 Nov;28(5):719-25. doi: 10.1093/jac/28.5.719.
8
In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Chemotherapy. 1998 Mar-Apr;44(2):85-93. doi: 10.1159/000007097.
9
Activity of new quinolones against ciprofloxacin-resistant staphylococci.
Antimicrob Agents Chemother. 1991 Aug;35(8):1679-81. doi: 10.1128/AAC.35.8.1679.
10
Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Antimicrob Agents Chemother. 1994 Jul;38(7):1671-4. doi: 10.1128/AAC.38.7.1671.
引用本文的文献
1
Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.
Antimicrob Agents Chemother. 1999 Sep;43(9):2295-8. doi: 10.1128/AAC.43.9.2295.
2
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.
Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522.
3
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
4
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.
Antimicrob Agents Chemother. 1998 May;42(5):1269-73. doi: 10.1128/AAC.42.5.1269.
5
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
Drugs. 1997 Apr;53(4):700-25. doi: 10.2165/00003495-199753040-00010.
6
Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.
Antimicrob Agents Chemother. 1996 Mar;40(3):776-9. doi: 10.1128/AAC.40.3.776.
7
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.
Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010.
8
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
Antimicrob Agents Chemother. 1996 Jun;40(6):1564-8. doi: 10.1128/AAC.40.6.1564.
9
Initial clinical experience with clinafloxacin in the treatment of serious infections.
Drugs. 1995;49 Suppl 2:488-91. doi: 10.2165/00003495-199500492-00145.
10
In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.
Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7. doi: 10.1128/AAC.39.9.2123.
本文引用的文献
1
The in-vitro activity of PD127,391, a new quinolone.
J Antimicrob Chemother. 1988 Aug;22(2):135-41. doi: 10.1093/jac/22.2.135.
2
Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.
Antimicrob Agents Chemother. 1988 Aug;32(8):1278-81. doi: 10.1128/AAC.32.8.1278.
3
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Antimicrob Agents Chemother. 1989 Aug;33(8):1167-73. doi: 10.1128/AAC.33.8.1167.
4
In vitro activity of AT-4140 against clinical bacterial isolates.
Antimicrob Agents Chemother. 1989 Nov;33(11):1980-8. doi: 10.1128/AAC.33.11.1980.
5
Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates.
Eur J Clin Microbiol Infect Dis. 1990 Apr;9(4):298-301. doi: 10.1007/BF01968067.
6
In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent.
Antimicrob Agents Chemother. 1991 Jan;35(1):141-6. doi: 10.1128/AAC.35.1.141.
Zotero 插件